Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170)

Please use this identifier to cite or link to this item: https://dspace.uzhnu.edu.ua/jspui/handle/lib/10601

Full metadata record

DC Field	Value	Language
dc.contributor.author	Готько, Євген Степанович	-
dc.contributor.author	T. Pinter P.K. Morrow A. Cesas A. Croitoru J. Decaestecker P. Gibbs	-
dc.contributor.author	J. Jassem G. Kurteva J. Novotny S. O'Reilly T. Salek L. Khosrowshahi M. Reiner Z. Klippel C. Blanke	-
dc.date.accessioned	2016-11-11T11:10:28Z	-
dc.date.available	2016-11-11T11:10:28Z	-
dc.date.issued	2015	-
dc.identifier.uri	https://dspace.uzhnu.edu.ua/jspui/handle/lib/10601	-
dc.language.iso	en	uk
dc.publisher	Gastroentérologie Clinique et Biologique Vol 33, N° HS1 - mars 2009 p. 139	uk
dc.title	Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170)	uk
dc.type	Text	uk
dc.pubType	Стаття	uk
Appears in Collections:	Наукові публікації кафедри радіології та онкології

Files in This Item:

File	Description	Size	Format
main.pdf.png		214.81 kB	image/png	View/Open